| Dr Justin M Weis, MD | |
|
350 Parrish St, Canandaigua, NY 14424-1731 | |
| (585) 396-6636 | |
| (585) 396-6492 |
| Full Name | Dr Justin M Weis |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 17 Years |
| Location | 350 Parrish St, Canandaigua, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245356468 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | 254935 (New York) | Secondary |
| 207R00000X | Internal Medicine | 254935 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| F F Thompson Hospital | Canandaigua, NY | Hospital |
| Strong Memorial Hospital | Rochester, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St James Hospital | 0345154480 | 111 |
| The Frederick Ferris Thompson Hospital | 3274428586 | 197 |
| Pulmonary Disease Clinical Group | 6608821657 | 62 |
| Mary M Parkes Asthma And Pulmonary | 9436126596 | 28 |
News Archive
Avanir Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted the company's Investigational New Drug (IND) application for the study of AVP-923, an investigational drug for the treatment of agitation in patients with Alzheimer's disease (AD).
Researchers at Children's Hospital of Philadelphia have developed a novel treatment for sepsis - one of the leading causes of hospital death - that enhances the body's bacteria-capturing neutrophil extracellular traps so that they more effectively capture infectious bacteria, resist degradation, and improve sepsis outcomes and survival.
Reversible infantile liver failure (RILF) is a heritable mitochondrial condition that causes severe liver dysfunction in infancy, but those who survive the acute stage typically recover and have no further problems.
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Research Foundation of the State University of New York (SUNY), acting for and on behalf of Binghamton University (Binghamton, NY).
› Verified 3 days ago
| Entity Name | St James Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699839431 PECOS PAC ID: 0345154480 Enrollment ID: O20031113000649 |
News Archive
Avanir Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted the company's Investigational New Drug (IND) application for the study of AVP-923, an investigational drug for the treatment of agitation in patients with Alzheimer's disease (AD).
Researchers at Children's Hospital of Philadelphia have developed a novel treatment for sepsis - one of the leading causes of hospital death - that enhances the body's bacteria-capturing neutrophil extracellular traps so that they more effectively capture infectious bacteria, resist degradation, and improve sepsis outcomes and survival.
Reversible infantile liver failure (RILF) is a heritable mitochondrial condition that causes severe liver dysfunction in infancy, but those who survive the acute stage typically recover and have no further problems.
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Research Foundation of the State University of New York (SUNY), acting for and on behalf of Binghamton University (Binghamton, NY).
› Verified 3 days ago
| Entity Name | University Of Rochester |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710226824 PECOS PAC ID: 5799699088 Enrollment ID: O20031201000019 |
News Archive
Avanir Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted the company's Investigational New Drug (IND) application for the study of AVP-923, an investigational drug for the treatment of agitation in patients with Alzheimer's disease (AD).
Researchers at Children's Hospital of Philadelphia have developed a novel treatment for sepsis - one of the leading causes of hospital death - that enhances the body's bacteria-capturing neutrophil extracellular traps so that they more effectively capture infectious bacteria, resist degradation, and improve sepsis outcomes and survival.
Reversible infantile liver failure (RILF) is a heritable mitochondrial condition that causes severe liver dysfunction in infancy, but those who survive the acute stage typically recover and have no further problems.
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Research Foundation of the State University of New York (SUNY), acting for and on behalf of Binghamton University (Binghamton, NY).
› Verified 3 days ago
| Entity Name | Mary Imogene Bassett Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083664221 PECOS PAC ID: 3779488325 Enrollment ID: O20031205000553 |
News Archive
Avanir Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted the company's Investigational New Drug (IND) application for the study of AVP-923, an investigational drug for the treatment of agitation in patients with Alzheimer's disease (AD).
Researchers at Children's Hospital of Philadelphia have developed a novel treatment for sepsis - one of the leading causes of hospital death - that enhances the body's bacteria-capturing neutrophil extracellular traps so that they more effectively capture infectious bacteria, resist degradation, and improve sepsis outcomes and survival.
Reversible infantile liver failure (RILF) is a heritable mitochondrial condition that causes severe liver dysfunction in infancy, but those who survive the acute stage typically recover and have no further problems.
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Research Foundation of the State University of New York (SUNY), acting for and on behalf of Binghamton University (Binghamton, NY).
› Verified 3 days ago
| Entity Name | The Frederick Ferris Thompson Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194776351 PECOS PAC ID: 3274428586 Enrollment ID: O20040217000109 |
News Archive
Avanir Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted the company's Investigational New Drug (IND) application for the study of AVP-923, an investigational drug for the treatment of agitation in patients with Alzheimer's disease (AD).
Researchers at Children's Hospital of Philadelphia have developed a novel treatment for sepsis - one of the leading causes of hospital death - that enhances the body's bacteria-capturing neutrophil extracellular traps so that they more effectively capture infectious bacteria, resist degradation, and improve sepsis outcomes and survival.
Reversible infantile liver failure (RILF) is a heritable mitochondrial condition that causes severe liver dysfunction in infancy, but those who survive the acute stage typically recover and have no further problems.
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Research Foundation of the State University of New York (SUNY), acting for and on behalf of Binghamton University (Binghamton, NY).
› Verified 3 days ago
| Entity Name | Mary M Parkes Asthma & Pulmonary |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588610760 PECOS PAC ID: 9436126596 Enrollment ID: O20040916000932 |
News Archive
Avanir Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted the company's Investigational New Drug (IND) application for the study of AVP-923, an investigational drug for the treatment of agitation in patients with Alzheimer's disease (AD).
Researchers at Children's Hospital of Philadelphia have developed a novel treatment for sepsis - one of the leading causes of hospital death - that enhances the body's bacteria-capturing neutrophil extracellular traps so that they more effectively capture infectious bacteria, resist degradation, and improve sepsis outcomes and survival.
Reversible infantile liver failure (RILF) is a heritable mitochondrial condition that causes severe liver dysfunction in infancy, but those who survive the acute stage typically recover and have no further problems.
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Research Foundation of the State University of New York (SUNY), acting for and on behalf of Binghamton University (Binghamton, NY).
› Verified 3 days ago
| Entity Name | Pulmonary Disease Clinical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881641652 PECOS PAC ID: 6608821657 Enrollment ID: O20050314000309 |
News Archive
Avanir Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted the company's Investigational New Drug (IND) application for the study of AVP-923, an investigational drug for the treatment of agitation in patients with Alzheimer's disease (AD).
Researchers at Children's Hospital of Philadelphia have developed a novel treatment for sepsis - one of the leading causes of hospital death - that enhances the body's bacteria-capturing neutrophil extracellular traps so that they more effectively capture infectious bacteria, resist degradation, and improve sepsis outcomes and survival.
Reversible infantile liver failure (RILF) is a heritable mitochondrial condition that causes severe liver dysfunction in infancy, but those who survive the acute stage typically recover and have no further problems.
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Research Foundation of the State University of New York (SUNY), acting for and on behalf of Binghamton University (Binghamton, NY).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Justin M Weis, MD 601 Elmwood Ave, Box 692, Rochester, NY 14642-0001 Ph: (585) 275-4161 | Dr Justin M Weis, MD 350 Parrish St, Canandaigua, NY 14424-1731 Ph: (585) 396-6636 |
News Archive
Avanir Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted the company's Investigational New Drug (IND) application for the study of AVP-923, an investigational drug for the treatment of agitation in patients with Alzheimer's disease (AD).
Researchers at Children's Hospital of Philadelphia have developed a novel treatment for sepsis - one of the leading causes of hospital death - that enhances the body's bacteria-capturing neutrophil extracellular traps so that they more effectively capture infectious bacteria, resist degradation, and improve sepsis outcomes and survival.
Reversible infantile liver failure (RILF) is a heritable mitochondrial condition that causes severe liver dysfunction in infancy, but those who survive the acute stage typically recover and have no further problems.
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Research Foundation of the State University of New York (SUNY), acting for and on behalf of Binghamton University (Binghamton, NY).
› Verified 3 days ago
Richard Benivegna, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 400 Fort Hill Ave, Canandaigua, NY 14424 Phone: 585-394-2000 | |
Dr. Thomas Wong, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 400 Fort Hill Ave, Canandaigua, NY 14424 Phone: 585-393-7401 | |
Marlys A Howarth, D.O. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 350 Parrish St, Canandaigua, NY 14424 Phone: 585-396-6000 | |
Dr. Katie Alison Smith, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 335 Parrish St, Canandaigua, NY 14424 Phone: 585-393-2888 Fax: 585-919-2539 | |
Dr. Gary G Kochersberger, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 350 Parrish St, Canandaigua, NY 14424 Phone: 585-396-6000 | |
Dr. Robert Barton Babcock, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 400 Fort Hill Ave, Canandaigua Va Medical Center, Canandaigua, NY 14424 Phone: 585-393-7211 Fax: 585-393-8328 | |
Dr. Leslie E Myers, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 335 Parrish St, Canandaigua, NY 14424 Phone: 585-393-2820 Fax: 585-396-9275 |